Zum Seiteninhalt springen

What is the IMPD and why is it so relevant early in the drug development process? What to consider? What do professional medical writers do and how do you get support from them?

The Investigational Medicinal Product Dossier (IMPD) is a central piece of documents required for approval of clinical trial applications by the regulatory authorities in the EU. The IMPD contributes to the overall success of drug development programs, and, for a first-in-human clinical trial, it is the initial document to assemble all obtained research data.

In this Online Educational Forum Lecture "Critical Facts about Writing an Investigational Medicinal Product Dossier (IMPD) for Successful Clinical Trial Applications", Dr. Carola Krause, President of the European Medical Writers Association (EMWA),and Abraham F. Shevack, past-President of the EMWA,will tell us about what to consider when preparing an IMPD for clinical trial applications and how you get support from professional medical writers.

After the online lecture, you will have insight into:

  • What is the Investigational Medicinal Product Dossier (IMPD) and why is it so relevant for successful clinical trial applications in the EU?
  • Why should you start with the IMPD early in the drug development process?
  • What are the timelines?
  • What is a professional medical writer doing?
  • How does the European Medical Writers Association (EMWA) support scientists?

Dr. Carola Krause, based in Potsdam Germany, is a workshop leader on IMPD writing and currently serves as the president of the EMWA. She has been offering a professional biomedical writing consultancy service to the pharmaceutical industry since 2016. Her multidisciplinary background in academic and pharmaceutical project management, and clinical trial coordination provides her with key insights into all phases of the drug development process and its regulatory requirements. Krause serves the European Commission as external HORIZON EUROPE and EUROSTARS expert.

Abraham F. Shevack, based in Berlin Germany, is past-President of the EMWA (2017-2018), workshop leader, and Chair of EMWA Ambassador’s Programme. He is a biologist with over 15 years in basic research in molecular biology in both academia and industry. Shevack has been a senior scientific medical writer for over 20 years with Schering and Bayer, preparing documents for global regulatory submissions in the EU, Asia Pacific region, and the USA. Since 2016, Shevack is a freelance medical writer and consultant with clients in pharma and biotech.


SPARK-BIH is a mentoring program that supports academic inventions with education, mentorship and funding. The program is designed to de-risk projects with high potential impact, addressing critical unmet medical needs for any indication. Our aim is to accelerate the translation of academic inventions into outstanding medical products including drugs, diagnostics and medical devices.


Who and what?
Dr. Carola Krause & Abraham F. Shevack
"Critical Facts about Writing an Investigational Medicinal Product Dossier (IMPD) for Successful Clinical Trial Applications"

Tuesday, 22 March 2022
4:00 - 5:00 pm (CET)

Online via Microsoft Teams
Please note that you will receive the Microsoft Teams link the evening before the lecture and that access to last minute registrations cannot be guaranteed.

Please register here!
Registration to the webinar is required in advance. Please register no later than 21 March 2022.